Shares of Inspire Medical Systems, Inc. (NYSE:INSP – Get Free Report) traded down 5.4% during trading on Tuesday after Zacks Research downgraded the stock from a strong-buy rating to a hold rating. The stock traded as low as $71.62 and last traded at $71.6260. Approximately 577,956 shares changed hands during trading, a decline of 47% from the average session volume of 1,081,862 shares. The stock had previously closed at $75.72.
Other equities research analysts have also recently issued reports about the company. Stifel Nicolaus raised their price target on Inspire Medical Systems from $75.00 to $80.00 and gave the company a “buy” rating in a report on Friday, September 11th. UBS Group began coverage on Inspire Medical Systems in a research report on Tuesday, July 28th. They set a “sell” rating and a $39.00 target price for the company. KeyCorp reissued a “sector weight” rating on shares of Inspire Medical Systems in a report on Tuesday, August 4th. Mizuho increased their price objective on shares of Inspire Medical Systems from $55.00 to $65.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. Finally, Freedom Capital raised shares of Inspire Medical Systems to a “strong-buy” rating in a report on Tuesday, June 30th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $66.50.
Insiders Place Their Bets
Institutional Investors Weigh In On Inspire Medical Systems
Several institutional investors have recently made changes to their positions in INSP. Alberta Investment Management Corp purchased a new stake in Inspire Medical Systems in the 2nd quarter valued at about $5,483,000. GSA Capital Partners LLP purchased a new stake in shares of Inspire Medical Systems during the second quarter worth about $820,000. Assenagon Asset Management S.A. increased its stake in Inspire Medical Systems by 66.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 864,395 shares of the company’s stock valued at $38,561,000 after purchasing an additional 344,221 shares in the last quarter. Bank of Nova Scotia increased its position in shares of Inspire Medical Systems by 49.8% in the 1st quarter. Bank of Nova Scotia now owns 60,000 shares of the company’s stock valued at $3,095,000 after acquiring an additional 19,958 shares during the period. Finally, Legal & General Group Plc purchased a new position in shares of Inspire Medical Systems in the second quarter worth about $2,732,000. Institutional investors own 94.91% of the company’s stock.
Inspire Medical Systems Trading Down 3.1%
The company has a market capitalization of $2.00 billion, a PE ratio of 14.95, a price-to-earnings-growth ratio of 5.39 and a beta of 0.70. The business’s 50-day simple moving average is $60.79 and its 200-day simple moving average is $53.18.
Inspire Medical Systems (NYSE:INSP – Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.38. The business had revenue of $200.58 million for the quarter, compared to analysts’ expectations of $194.72 million. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The business’s revenue was down 7.6% on a year-over-year basis. During the same quarter last year, the company earned $0.45 EPS. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. Sell-side analysts forecast that Inspire Medical Systems, Inc. will post 1.24 EPS for the current fiscal year.
About Inspire Medical Systems
Inspire Medical Systems, Inc develops and commercializes medical devices for treating moderate to severe obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly becomes blocked during sleep. The company’s primary product is Inspire therapy, an implantable system designed for patients who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.
The Inspire system uses a small implantable pulse generator, a breathing-sensing lead and a stimulation lead.
Featured Stories
- Five stocks we like better than Inspire Medical Systems
- 3 Energy ETFs Built for Oil’s New $100-Plus Reality
- Can Marvell Keep Up in the Custom AI Chip Race?
- DraftKings Falls 7.6%: Is Kalshi’s NFL Lead Really That Big?
- Gaming Your Portfolio: Should You Add Take-Two Ahead of GTA 6’s November Launch?
Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
